



*Just What Women
Want in Healthcare*

Agile Therapeutics to Speak at Late Phase Drug Development World Americas 2012

-- Chief Medical Officer to Discuss Challenges in Phase IIIb and IV Studies --

PRINCETON, N.J. – March 22, 2012 – Agile Therapeutics, a pharmaceutical company focused on developing and commercializing more convenient women’s contraceptive products, announced today that Dr. Marie Foegh, Chief Medical Officer and Vice President of Clinical Research and Development at Agile, will be a featured speaker at Late Phase Drug Development World Americas 2012. As part of the panel entitled “*Challenges in Outcome Trials*,” Dr. Foegh will discuss the challenges encountered in phase IIIb and IV studies with female health products on Thursday, March 22nd from 9:40 am to 10:10 am Eastern. Late Phase Drug Development World Americas 2012 will be held in Boston at the Hyatt Regency Boston from March 21st through 22nd.

“Navigating the challenges of late stage clinical development has become increasingly difficult due to changes in the population participating in clinical trials and the evolving regulatory and competitive economic environment,” said Dr. Foegh. “Armed with the right skill set and unwavering focus, however, it is possible for even small companies such as Agile Therapeutics to conduct world-class clinical trials. Conferences such as Late Phase Drug Development are very valuable as they offer companies the opportunity to learn from each other’s experience.”

Agile has recently completed Phase III trials on a low-dose contraceptive patch and plans the NDA submission within the next couple of weeks.

About Agile Therapeutics

Agile Therapeutics is a pharmaceutical development company specializing in women’s healthcare products, with an initial focus on providing women with more options and more convenient methods of hormonal contraception. The company’s lead product, AG200-15, is a once-weekly contraceptive patch that recently completed Phase III clinical trials. In addition, Agile is also developing a low dose, progestin-only contraceptive patch, AG890. Both AG200-15 and AG890 incorporate proprietary transdermal delivery technology, Skinfusion™, developed by Agile, consisting of an active and peripheral adhesive system that allows stable drug delivery and dependable adhesion over seven days. For more information, please visit <http://www.agiletherapeutics.com>.

About Late Phase Drug Development World Americas 2012

Late Phase Drug Development World Americas 2012, organized by Health Network Communications, focuses on driving value in phase IIIb and IV trials. The event offers opportunities for professionals in the pharmaceutical world to share strategies for building cost-effective, non-interventional studies, effectively collecting, validating, and



*Just What Women
Want in Healthcare*

analyzing observational data, gaining market access globally based on late phase data, and turning real world insight into a commercial asset. For more information, please visit <http://www.healthnetworkcommunications.com/2012/late-phase-drug-development>.

Contact:

Chantal Beaudry or Karen Famighetti for Agile Therapeutics

cbeaudry@lazarpartners.com

kfamighetti@lazarpartners.com

212-867-1762